Canada has approved generic semaglutide. The US wall holds to at least 2032
The foundational patent expired 20 March 2026 in four markets and lapsed in Canada, which approved its first two generics in April and May.
GLP-1 and Peptide News: What Changed, and When
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · journal · corrections.
A dated log of what changed in this market. 12 items, newest August 4, 2026. Every entry names its source; where a figure has been withdrawn, the corrections log says so.
Updated as sources change, not on a schedule. The most recent item is dated August 4, 2026.
BPC-157 is on the FDA's Category 2 bulks list. It is still widely sold
Category 2 identifies substances raising significant safety risks, which may not be used in 503A compounding. BPC-157 has no human efficacy trials.
The approved oral tablet is a ladder, not a flat rate: $149 at starter doses, $299 at maintenance
The manufacturer's own price guide sets the oral tablet at $149 for 1.5 and 4 mg and $299 for the 9 and 25 mg maintenance doses. The 4 mg rate ends 31 August 2026.
Manufacturer prices are national. What varies by state is whether anyone else pays them
Medicaid coverage of the obesity indication is a state-by-state decision, and many programmes cover GLP-1s for diabetes while excluding obesity.
Five free databases settle whether a GLP-1 provider is what it says. All five need one thing first
State board registers, FDA warning letters, the 503B list and openFDA recalls are all searchable by company name — which is why a provider that will not name its pharmacy has ended the conversation.
Two-thirds of lost weight returned within a year of stopping, and that reframes every price comparison
The STEP-1 extension and SURMOUNT-4 both report regain on withdrawal. If treatment is ongoing, annual maintenance cost is the figure that matters.
Four pricing structures separate an advertised GLP-1 figure from what lands on your card
Membership fees outside the headline, dose tiers, introductory rates and prepay-only pricing. They stack, and all four are visible if you ask four questions.
Eighteen months after the shortage ended, what is left of compounded GLP-1s
The mass-compounding pathway closed on 21 February 2025. 503A patient-specific compounding continues, and it requires a documented clinical reason.
Two approved generic GLP-1s exist, and both are liraglutide
A generic referencing Victoza was approved in December 2024 and one referencing Saxenda in August 2025. It is the cheapest approved route and the least effective.
GLP-1 side effects follow the dose schedule, not the calendar
Gastrointestinal effects cluster around each dose increase. In STEP-1, nausea affected roughly 44% against about 18% on placebo, and about 7% discontinued.
Tesamorelin is approved for one indication, and almost none of its marketing describes that population
Egrifta is approved for excess visceral abdominal fat in HIV-associated lipodystrophy. It is not approved for general fat loss, body recomposition or anti-ageing.
GLP-1s slow gastric emptying, and a standard pre-operative fast may not empty the stomach
Anaesthesia guidance exists because case reports described residual gastric contents after adequate fasting. It applies to compounded products too.